Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 526 to 540 of 667 results for kidney or kidneys or renal

  1. Risk assessment, referral criteria and shared care: What is the association between risk factors and CKD outcomes in children and young people?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  2. Investigations for proteinuria: In children and young people, what is the accuracy of reagent strips for detecting albumin in urine?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  3. Managing anaemia: What are the long-term consequences of high ferritin levels (above 800 micrograms/litre) in children and young people with CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  4. Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)

    Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.

    Technology appraisal guidance
    Published
    16 December 2020
    View recommendations

    Sections for TA667

  5. Self-management of CKD: Does the provision of educational and supportive interventions to people with CKD by healthcare professionals increase the person's skills and confidence in managing their conditions and improve clinical outcomes?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  6. Vitamin D supplements in the management of CKD–mineral and bone disorders: In people with hyperparathyroidism secondary to CKD, does treatment with vitamin D or vitamin D analogues improve patient-related outcomes?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  7. Antiplatelet therapy: For people with CKD at the highest risk of cardiovascular disease, what is the clinical effectiveness of low-dose aspirin compared with placebo for primary prevention of cardiovascular disease?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  8. Phosphate binders: Which binders are the most clinically and cost effective in controlling serum phosphate in adults, children and young people with stage 4 or 5 CKD who are not on dialysis?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  9. Investigations for proteinuria: What is the effect of measuring proteinuria with albumin:creatinine ratio compared with protein:creatinine ratio on the timing of treatment changes in children and young people with CKD? [2021]

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  10. Care of dying adults in the last days of life (NG31)

    This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.

    NICE guideline
    Published
    16 December 2015
    View recommendations

    Sections for NG31

  11. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

    NICE guideline
    Last updated
    22 March 2021
    View recommendations

    Sections for NG144

  12. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (IPG536)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

    Interventional procedures guidance
    Published
    25 November 2015
    View recommendations

    Sections for IPG536

  13. Managing anaemia: For adults, children and young people with CKD and anaemia, what is the diagnostic accuracy of eGFR thresholds of 60, 45, and 30 ml/min/1.73 m2 for determining whether the anaemia is due to CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  14. Managing anaemia: For adults, children and young people with CKD and anaemia who are on peritoneal dialysis, what amount of intravenous (IV) iron is most clinically and cost effective in managing anaemia and its associated outcomes (including quality of life)?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  15. Management of anaemia of CKD with concurrent illness: What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of CKD in people who are receiving erythropoietic stimulating agents (ESAs) and have a significant concurrent acute infectious illness?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021